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Abstract: Real-time monitoring of tumor microenvironment
parameters using an implanted biosensor could provide valu-
able information on the dynamic nature of a tumor’s biology
and its response to treatment. However, following implanta-
tion biosensors may lose functionality due to biofouling
caused by the foreign body response (FBR). This study devel-
oped a novel tumor xenograft model to evaluate the potential
of six biomaterials (silicon dioxide, silicon nitride, Parylene-C,
Naﬁon, biocompatible EPOTEK epoxy resin, and platinum) to
trigger a FBR when implanted into a solid tumor. Biomaterials
were chosen based on their use in the construction of a novel
biosensor, designed to measure spatial and temporal changes
in intra-tumoral O2, and pH. None of the biomaterials had any
detrimental effect on tumor growth or body weight of the
murine host. Immunohistochemistry showed no signiﬁcant
changes in tumor necrosis, hypoxic cell number, proliferation,
apoptosis, immune cell inﬁltration, or collagen deposition. The
absence of biofouling supports the use of these materials in
biosensors; future investigations in preclinical cancer models
are required, with a view to eventual applications in humans.
To our knowledge this is the ﬁrst documented investigation of
the effects of modern biomaterials, used in the production of
implantable sensors, on tumor tissue after implantation. © 2018
The Authors. Journal of Biomedical Materials Research Part B: Applied
Biomaterials Published by Wiley Periodicals, Inc. J Biomed Mater Res B
Part B: 00B: 000–000, 2018.
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INTRODUCTION
Cancer is a leading cause of mortality, resulting in personal,
economic and social burdens in developing and developed
countries alike.1 Novel diagnostic, monitoring, and treatment
regimens are required if long-term survival rates are to be
improved. The metabolic processes within solid tumors
differ from those in normal tissues. Areas within tumors can
be deprived of O2, glucose and energy, while experiencing
extracellular acidosis, high lactate levels and interstitial
hypertension, caused by abnormal tumor vasculature.2
Monitoring the tumor microenvironment (TME) for cancer
biomarkers, metabolites, pH, and O2 could provide data to
target hypoxic areas more effectively by radiation and anti-
cancer drugs; data could also be used to monitor the
response of a tumor to treatment, detect residual or recur-
rent disease and help understand the biological events that
drive the metastatic process.3,4
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Identiﬁcation of hypoxic areas within solid tumors is
clinically important as hypoxic cancer cells are more resis-
tant to chemo/radiotherapy, with increased invasive and
metastatic potential. Advanced radiotherapy (RT) delivery
systems allow dose distribution to be applied with great
accuracy to tumors while sparing normal tissues.5 Conven-
tional curative RT schedules for solid tumors (e.g., lung, head
and neck, breast) deliver the same dose distribution to the
whole tumor based on a baseline radiation distribution plan
in a series of fractions over several weeks. Continuous intra-
tumoral monitoring of oxygenation could create a changing
map of the distribution of hypoxia. This would enable dose
distribution to be modulated, optimized, and individualized
on a daily basis to improve tumor response. Additional dos-
age could also be delivered to hypoxic areas. An implantable
biosensor taking intra-tumoral real-time O2 readings would
provide information at the time of treatment, monitoring
spatial, and temporal changes thus overcoming the limita-
tions associated with current technologies to measure tumor
oxygenation status. The Implantable Microsystems for Perso-
nalised Anti-Cancer Therapy (IMPACT) project (www.impact.
eng.ed.ac.uk) aims to produce such a device, allowing RT to
be delivered at the most effective location and time by tar-
geting these hypoxic regions.4
Implantable peri-tumoral or intra-tumoral devices could
also be developed to release chemotherapeutic drugs directly
within the TME, increasing the drugs therapeutic potential
while reducing the severity of systemic side effects.6 Implant-
able devices have also been used in radiation oncology; an
implantable dosimeter has been developed to verify the radia-
tion dose received by the target volume for each fraction the
patient receives.3 This dosimeter has undergone clinical test-
ing and received FDA approval for use in breast and prostate
cancer and can allow a radiation oncologist to optimize radia-
tion treatment on an individual basis.
For implantable devices to gain clinical approval, their
biocompatibility, incorporating both bio-functionality and
biosafety, must be investigated.7–10 Unfortunately, the bio-
compatibility of implantable devices remains a challenge as
biosensors typically lose functionality over time; this detri-
mental effect is largely due to biofouling (non-speciﬁc cell/
protein absorption) that occurs locally around the device,
resulting in a tissue reaction known as the foreign body
response (FBR).11–13 Biocompatibility can also be viewed as a
characteristic of a system and not of a speciﬁc material; indi-
vidual materials may therefore affect different biological sys-
tems in different ways.13–15 The focus of the FBR currently
relates to materials that are implanted into normal tissue,
with numerous in vivo models available for biocompatibility
testing.16–20 If medical devices are developed for implantation
within or near tumor tissue, then the FBR must also be evalu-
ated within these diseased tissues, rather than relying on pre-
viously published FBR data from implantation within healthy
tissue alone. The purpose of this study was to develop a novel
murine model where biomaterials, that were under consider-
ation for use in the IMPACT biosensor, could be safely and
reproducibly implanted into human cancer cell xenografts.
Novel methodology was developed to process tumors while
biomaterials were still present and to section them to identify
the implant site. The effects of the biomaterials were investi-
gated through changes in body weights and mean tumor vol-
umes, while immunohistochemistry was used to assess
necrosis, proliferation, apoptosis and hypoxic markers, as well
as innate immune responses and ﬁbrosis within the tumor.
Literature searches indicate that this is the ﬁrst report of the
interaction of modern biomaterials used in implantable bio-
sensor technology with a TME.
MATERIALS AND METHODS
Biomaterial fabrication
The IMPACT biosensor consists of a microfabricated silicon
chip insulated in biocompatible resin. The outward-facing
materials of the biosensor were selected for testing; these
were: silicon dioxide (SiO2), silicon nitride (Si3N4), Parylene-
C, Naﬁon, OG116-31 resin (Epoxy Technology), and platinum
(Pt). Materials were prepared in the Scottish Microelectron-
ics Centre Class 10 cleanroom facility (Kings Buildings, Uni-
versity of Edinburgh) and comprised of 3–7 mm long pieces
of titanium (Ti) wire, diameter 0.4 mm, coated with the
material to be tested. Copper (Cu) wire (Sigma Aldrich,
99.999% purity) was used for positive control samples.
Biomaterial manufacture
For all coated biomaterials Ti wire was ﬁrst cleaned in iso-
propyl alcohol at 50C with ultrasonic agitation for 15 min,
followed by the same treatment in deionized water, then
dried using an N2 gun; Cu wire was also cleaned using the
same protocol. Parylene-C samples were produced using a
vapor deposition system SCS (Speciality Coating Systems
2010 Labcoater) ensuring a conformal coating of 5 μm of
Parylene-C. SiO2 and Si3N4 samples were prepared using
Plasma Enhanced Chemical Vapour Deposition (PECVD); a
1 μm layer of each material was deposited. Pt samples were
produced using electron-beam evaporation in an ANS Cluster
tool which deposited a 50 nm thick Pt ﬁlm onto the wire.
Naﬁon samples were created by dipping Ti wire in a solution
of 5% by weight Naﬁon in lower aliphatic alcohols and
water, before air curing for 5 min; the process was repeated
ﬁve times before curing at 120C for 1 h.21 Resin samples
were produced by dip coating the Ti wire in OG116-31 resin
then curing for 800 s under ultraviolet light. After comple-
tion of each coating process the wires were optically
inspected to ensure uniformity.
Generation of MDA-MB-231 xenograft tumors
Murine studies were undertaken under a UK Home Ofﬁce
Project Licence. The study was performed in accordance
with the Animals (Scientiﬁc Procedures) Act 1986, which
was approved by the University of Edinburgh Animal Ethics
Committee. Recommended guidelines for welfare and use of
animals in research were followed. CD-1 immunodeﬁcient
female nude mice (Charles River Laboratories, Tranent, UK)
of at least 8 weeks of age were allowed a period of adapta-
tion in a sterile, pathogen-free environment, with ad libitum
access to food and water. Mice were housed in individually
ventilated cages in a barrier environment.
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MDA-MB-231 human breast tumor cells (originally
obtained from ATCC) were grown routinely for the genera-
tion of stock xenografts. Approximately 2 × 109 MDA-MB-
231 cells were re-suspended in 1 mL of serum-free DMEM
(Gibco® Life Technologies, Invitrogen, UK), with 0.1 mL of
this cell suspension injected bilaterally into subcutaneous
tissue of the ﬂanks of ﬁve mice. Once stock tumors had
grown sufﬁciently (6 weeks) they were harvested and sec-
tioned into 1–2 mm long fragments before implantation into
experimental mice under local anesthetic (ethyl chloride)
using a 12 G trocar. Each mouse received two tumor frag-
ments injected bilaterally into subcutaneous ﬂank tissue.
Biomaterial implantation
Treatment groups consisted of xenograft tumors implanted
with biomaterial, controls (xenograft tumors that received a
needle tract (NT) injury) and an untreated group. Bilateral
tumor generation allowed the total number of mice required
to be reduced as each mouse acted as its own control; one
tumor received biomaterial implantation or NT injury while
the contralateral tumor was left untreated. Naﬁon coated
wires were sterilized by routine autoclaving; all other bioma-
terials were sterilized in 100% ethanol for 10 min, rinsed in
deionized water and stored in penicillin and streptomycin.
All wires were washed in sterile distilled water immediately
before implantation.
Mice underwent general anesthesia using isoﬂurane gas-
eous anesthesia for implantation (deﬁned as day 0). Skin
was aseptically prepared using chlorohexidine solution. For
biomaterial implantation, a 21 G needle was used to pene-
trate the skin overlying the tumor but did not enter the
tumor parenchyma itself. This entry point was located at the
caudal aspect of the tumor so introduction of the biomaterial
would be along the long axis. Biomaterial was then intro-
duced into the tumor through the pre-prepared entry point.
Tissue adhesive (Vetbond™, 3M) was applied to the skin.
For NT control tumors, a 21 G needle was used to penetrate
the skin then advanced into the tumor tissue itself. A mini-
mum of ﬁve mice were used in each treatment group.
Day 0 mice were euthanized immediately after anesthesia,
with the remaining mice monitored up to 7 days post-
implantation. Mice were assessed for signs of ill health with
body weights, body condition score, and tumor size mea-
sured three times a week. Vernier calipers were used to
measure tumor size. Tumor volume was calculated as π/6 ×
width2 × length. Relative tumor volume was calculated by
dividing the tumor volume on each day by its volume on
day 0.
Immunohistochemistry
Microtome sections of 4 μm were placed on SuperFrost®
Plus glass slides (Thermo Scientiﬁc™, UK) and dried over-
night at 37C. Sections for IHC underwent a routine IHC pro-
tocol and counterstaining in hematoxylin22 (Table I provides
details of all antibodies used in the study). Additional sec-
tions were also routinely stained with hematoxylin and eosin
(H&E) or Masson’s Trichrome (TCS Biosciences Ltd, UK). All
IHC slides were scanned using the NanoZoomer ER slide
scanner (Hamamatsu Photonics, UK) and viewed using
NanoZoomer Digital Pathology software (Figure 1).
Immunohistochemical analysis
Image analysis software QuPath version 0.1.2 (Queen’s
University, Belfast) was used to analyze target protein
expression and percentage area tumor necrosis. The percent-
age area of collagen was assessed with a color deconvolution
macro developed by L. Murphy (IGMM, University of Edin-
burgh, UK) using Image J (NIH, Bethesda, MD). All extrane-
ous tissue such as subcutaneous fat and skin was excluded
from image analysis. The staining pattern of each antibody
was veriﬁed by a board-certiﬁed veterinary pathologist (L.R.
Morrison, The Royal (Dick) School of Veterinary Studies,
Edinburgh).
Statistical analysis
Data was analyzed with parametric tests; one-way ANOVA
with Tukey’s multiple comparisons was used to test for dif-
ferences between more than two groups, and unpaired (two
tailed) t test was used to test for differences between two
groups. p values <0.05 were deemed statistically signiﬁcant.
Data expressed as mean  SEM.
TABLE I. Antibodies Used in This Study
Primary antibody
target antigen
Histological marker/
cited publications
Antibody details and
antigen retrieval solution Manufacturer Dilution
Anti-ki67 Proliferation23–26 Monoclonal rabbit
Sodium citrate
Abcam; ab92742 1:1000
Anti-carbonic anhydrase IX Hypoxia22,27,28 Polyclonal rabbit
Sodium citrate
Abcam: ab15086 1:750
Anti-cleaved caspase-3 Apoptosis29–32 Polyclonal rabbit
Sodium citrate
Cell Signalling Technology; 9661 1:150
Anti-Ly-6C/-6G Neutrophil33–36 Monoclonal Rat
EDTA
Abcam; ab25377 1:50
Anti-F4/80 Macrophage37–40 Monoclonal Rat
Enzymatic
Biolegend; 123101 1:100
Anti-ER-TR7 Fibroblast41–44 Monoclonal Rat
Enzymatic
Novus Biologicals; NB100-64932 1:50
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RESULTS
The effects of biomaterial implantation on mice body
weights and tumor volumes
The body weights of untreated, biomaterial (SiO2, Si3N4,
Parylene-C, Naﬁon, OG116-31 resin, and Pt) and positive
control (Cu) implanted mice remained stable throughout the
7-day experimental period, with no statistically signiﬁcant
changes in body weight observed within any treatment
group. Furthermore, no statistically signiﬁcant differences
were identiﬁed between the groups at each time point. Mean
tumor volumes for untreated, NT and biomaterial implanted
tumors all showed growth over the 7 days, with no statisti-
cal differences identiﬁed between any group at the time
points analyzed (Figure 2).
The effects of biomaterials on tumor necrosis and CA9
staining
Solid tumors typically have areas of necrosis. At 7 days post-
implantation Cu implanted tumors had a statistically signiﬁcant
increase in the area of necrosis compared to untreated
(p = 0.0122) and NT (p = 0.0361) control groups. No signiﬁcant
difference in the area of necrosis was identiﬁed between the
remaining biomaterial implanted tumors and control tumors.
CA9 is a marker of hypoxia. No signiﬁcant difference in the per-
centage of CA9 positive cells was identiﬁed between any of the
biomaterial implanted tumors and control tumors (Figure 3).
The effects of biomaterials on tumor proliferation and
apoptosis
Ki67 is a marker of cell proliferation. No signiﬁcant differ-
ence in the percentage of cells staining positive for Ki67 was
identiﬁed between any of the biomaterial implanted tumors
and control tumors. Cleaved caspase 3 is a marker of apopto-
sis. Only Cu implanted tumors had a statistically signiﬁcant
increase in the percentage of cleaved caspase 3 positive cells
compared to untreated (p = 0.0033) and NT (p = 0.0018)
control groups 7 days post-implantation (Figure 4).
The effects of biomaterials on neutrophil and
macrophage inﬁltration within tumor tissue
Ly6G/-6C is a marker of neutrophils and F4/80 is a marker
of macrophages. No signiﬁcant differences in the percentage
of Ly6G/-6C or F4/80 positive cells were identiﬁed between
any of the biomaterial implanted tumors and control tumors.
Only small numbers of Ly-6G/-6C positive cells were identi-
ﬁed in any of the tumors (Figure 5).
The effects of biomaterials on ﬁbroblast inﬁltration and
collagen deposition within tumor tissue
ER-TR7 is a marker of ﬁbroblasts. Compared to untreated
tumors at day 0, there was a signiﬁcantly higher percentage
of ER-TR7 positive cells in both untreated (p = 0.0073) and
NT injury tumors (p = 0.0445) at day 7. However, no signiﬁ-
cant differences in the percentage of ER-TR7 positive cells
were identiﬁed between any of the biomaterial implanted
tumors and control tumors at 7 days post-implantation.
Untreated tumors at day 7 also had a statistically signiﬁcant
higher percentage area of collagen compared to untreated
tumors at day 0 (p = 0.0055). Only Cu implanted tumors had
a statistically signiﬁcant increase in the percentage area of
collagen compared to untreated (p = 0.0135) and NT
FIGURE 1. Photographs depicting xenograft tumor processing and sectioning, along with representative H&E stained slides. (A–C) Photographs
depicting the position of the biomaterial within a xenograft tumor following harvesting and processing for IHC. The dashed box is outlining an
OG116-31 resin biomaterial wire. To identify the implant site, sectioning of the tissue block continued until the tip of the biomaterial was found. If
the biomaterial was approximately ﬂush with the cut surface the wire was removed and sectioning continued; however, if the direction of the wire
was further into the tumor, the parafﬁn was then melted, and the wire carefully removed. The tumor tissue was trimmed from its sectioned edge as
parallel as possible to the path of the wire tract before being re-embedded in parafﬁn. Once set, sectioning continued through the block. (D–G) Rep-
resentative H&E stained sections from untreated and biomaterial implanted xenograft tumors harvested at day 7. (D, E) Untreated, (F) Naﬁon
implanted, (G) SiO2 implanted.
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FIGURE 2. The effects of different biomaterials on mice body weights and tumor volumes. (Ai, Bi) Changes in mice body weights for untreated
xenograft tumors and Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors up to 7 days post-implantation. Body
weights were normalized to the day 0 value. (Aii, Bii) Mean tumor volumes for untreated and NT injury xenograft tumors, along with Cu, OG116-31
resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors up to 7 days post-implantation. Tumor volume at each time point was
normalized to its day 0 measurement.
FIGURE 3. The effects of biomaterials on tumor necrosis and CA9 staining. (Ai, Aii) Representative H&E stained sections from xenograft tumors har-
vested at day 7. (Ai) Untreated, (Aii) Cu. (Bi, Bii) Percentage area of necrosis for untreated and NT injury xenograft tumors, along with Cu, OG116-31
resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors up to 7 days post-implantation. (Ci, Cii) Representative CA9 stained sec-
tions from xenograft tumors harvested at day 7. (Ci) Untreated, (Cii) Naﬁon. (Di, Dii) Percentage of CA9 positive staining cells for untreated and NT
injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors up to 7 days post-
implantation.
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FIGURE 4. The effects of biomaterials on tumor proliferation and apoptosis. (Ai, Aii) Representative Ki67 stained sections from xenograft tumors
harvested at day 7. (Ai) Untreated, (Aii) SiO2. (Bi, Bii) Percentage of Ki67 positive staining cells for untreated and NT injury xenograft tumors, along
with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors at 7 days post-implantation. (Ci, Cii) Representative
caspase 3 stained sections from xenograft tumors harvested at day 7. (Ci) Untreated, (Cii) Cu. (Di, Dii) Percentage of caspase 3 positive staining cells
for untreated and NT injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors
at 7 days post-implantation.
FIGURE 5. The effects of biomaterials on neutrophil (Ly-6G/-6C) and macrophage (F4/80) inﬁltration within tumor tissue. (Ai, Aii) Representative Ly-
6G/-6C stained sections from xenograft tumors harvested at day 7. (Ai) Untreated, (Aii) Parylene-C. (Bi, Bii) Percentage of Ly-6G/-6C positive staining
cells for untreated and NT injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft
tumors at 7 days post-implantation. (Ci, Cii) Representative F4/80 stained sections from xenograft tumors harvested at day 7. (Ci) Untreated, (Cii)
Si3N4. (Di, Dii) Percentage of F4/80 positive staining cells for untreated and NT injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C,
Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors at 7 days post-implantation.
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(p = 0.0211) control groups at day 7 post-implantation
(Figure 6).
DISCUSSION
Interest in the use and development of implantable medical
devices has gained momentum in recent years due to their
potential roles in precision medicine, and because of techno-
logical advances in the development and fabrication of novel
biomaterials.10 However, any assessment of the ability of an
implantable medical device to provide meaningful data must
also consider the host response that occurs following
implantation. Biocompatibility consists of both biosafety
(i.e., appropriate local and systemic host responses with the
absence of cytotoxicity, mutagenesis, and/or carcinogenesis)
and biofunctionality (i.e., the ability of a device to function
with an appropriate host response in a speciﬁc application).9
To protect patient safety implantable medical devices
must conform to standards set by regulatory bodies. The
International Standards Agency (ISO) developed and pub-
lished international standards on the Biological Evaluation of
Medical Devices: ISO 10933; this documents a series of stan-
dards for biocompatibility evaluation of medical devices
prior to clinical testing.15,45 Various in vivo biocompatibility
models including the cage implant system,16 the chamber
system17 and the chorioallantoic membrane (CAM) of a
developing chick embryo model20 have been described pre-
viously; however, these models involve the implantation of
materials into normal tissue. If medical devices are
developed for implantation into diseased or tumor tissue,
then the FBR (as an aspect of biocompatibility) must also be
evaluated within these tissues.
Implantable medical devices for cancer treatment have
been developed in both clinical and experimental settings.3,6
However, only sparse information is available on the FBR
within tumor tissue. One historical paper did investigate the
FBR after the implantation of cotton thread into rodent
tumors, comparing the reaction to that observed in normal
tissues. The results showed that the responses seen in
tumors were minimal compared to normal tissues, indicating
that the FBR may be decreased within tumor tissue.46
Here, we assessed the biocompatibility of modern bioma-
terials under consideration for use in the IMPACT biosen-
sor.4 The biocompatibility of these biomaterials was
assessed up to 7 days post-implantation in a human breast
cancer xenograft tumor. Histological evaluation was used to
assess tumor cell proliferation, apoptosis, hypoxia, and the
extent of necrosis. To investigate the FBR, innate immune
cell markers encompassing both the acute and beginning of
the chronic inﬂammatory phases (including ﬁbrous encapsu-
lation) were assessed, with Cu used as a positive control.
Antibodies selected for use in this study depended on the
cell type of interest. Antibodies used to identify immune cells
were speciﬁcally chosen to detect murine cells, as no human
immune cells would be present within this xenograft tumor
model; we were therefore assessing the biomaterials effect
on the murine immune response rather than a human
FIGURE 6. The effects of biomaterials on ﬁbroblast (ER-TR7) inﬁltration and collagen deposition within tumor tissue. (Ai–Aii) Representative ER-TR7
stained sections from xenograft tumors harvested at day 7. (Ai) Untreated, (Aii) Pt. (Bi, Bii) Percentage of ER-TR7 positive staining cells for untreated
and NT injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4, and SiO2 implanted xenograft tumors up to 7 days
post-implantation. (Ci, Cii) Representative Masson’s trichrome stained sections from xenograft tumors harvested at day 7. (Ci) Untreated, (Cii) SiO2.
(Di, Dii) Percentage area of collagen for untreated and NT injury xenograft tumors, along with Cu, OG116-31 resin, Parylene-C, Naﬁon, Pt, Si3N4,
and SiO2 implanted xenograft tumors up to 7 days post-implantation. Data for (Di) graph is expressed as mean  SEM; according to unpaired two
sample t test. Data for (Dii) expressed as mean  SEM; according to one-way ANOVA followed by Tukey’s multiple comparison test.
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immune response. This was an important consideration,
especially with regards to the F4/80 antibody, as it is solely
a murine pan-macrophage marker. Conversely, antibodies
used to investigate ki67 and caspase 3 were required to tar-
get antigens present on the MDA-MB-231 human breast can-
cer cells.
Many previous studies have demonstrated the cytotoxic
effect of Cu47–49 mediated through a variety of different
mechanisms50,51; Cu and Cu ions can participate in the gener-
ation of reactive oxygen species (ROS),52 which can induce
DNA strand breaks and base oxidation, leading to cell death.53
Cu2+-induced apoptosis has also been shown to be mediated
through ROS, induction of Bax and inactivation of NF-κB.54
Cu induces a stronger inﬂammatory response in in vivo
models compared to non-Cu containing materials, while
also leading to larger ﬁbrous capsule development.55,56 In
our study, Cu implanted xenografts had larger areas of
necrosis and an increased percentage of caspase 3 positive
cells; the speciﬁc mechanism which resulted in Cu producing
these changes was not investigated, however, the increased
levels of apoptosis observed within the tumors does agree
with previously published work.54 While the absolute
percentage of ﬁbroblasts remained the same in the Cu
implanted tumors compared to untreated and NT injury
tumors, the percentage area of collagen was increased in Cu
implanted tumors, with collagen consisting of 1.05% of the
area within the Cu implanted tumors, compared with 0.49%
in NT injury tumors and 0.48% in untreated tumors
(Figure 6).
The biocompatibility of the biomaterials used in this
study has been previously well documented, with results
indicating that the materials are well tolerated with a mini-
mal FBR produced when implanted in vivo. These results
have led to the use of these biomaterials in a variety of med-
ical devices; a detailed summary of these devices can be
found in Table II. However, these previous biocompatibility
studies have used models in which materials are implanted
into healthy, non-diseased tissue. Our study was speciﬁcally
designed to examine the effects of biomaterial implantation
within a TME. No systemic toxicities were identiﬁed
(as indicated by the maintenance of body weight/body con-
dition), and all implanted tumors increased in size over
7 days in accordance with the controls. Assessment of prolif-
eration and apoptosis was performed through Ki67 and cas-
pase 3 staining respectively; no signiﬁcant differences in
cellular proliferation or apoptosis were observed between
any of the different treatment groups, indicating that the bio-
materials did not affect tumor cell viability. CA9 is a protein
induced in hypoxic conditions and is involved in pH regula-
tion22; expression of CA9 was investigated as the IMPACT
sensor is ultimately designed to monitor tumor O2 status. No
signiﬁcant differences in CA9 staining were observed
between any of the different treatment groups, indicating
that the biomaterials did not affect the O2 levels within the
tumor. MDA-MB-231 xenograft tumors are heterogeneous,
containing areas that are normoxic, hypoxic, and necrotic.103
The necrosis that develops is a result of the tumor outgrow-
ing its blood supply; although necrotic areas were identiﬁed
around the implanted materials, the necrotic areas measured
were not signiﬁcantly different from the controls, suggesting
no deleterious effects.
The FBR generated by an implanted biomaterial has been
shown to be affected by the materials modulus, stiffness and
mechanics, with materials having lower moduli producing
less ﬁbrous capsules than more rigid materials.104 Similarly,
materials with greater stiffness can cause increased com-
pression, expansion, and subsequent damage to the tissue in
which the material is implanted in.105 It is therefore thought
that softer materials, with properties similar to the implanta-
tion tissue, can reduce interfacial strain and improve bio-
compatibility.106 However, the results presented in this
study suggest that this may not be a major factor in this
tumor model, as no signiﬁcant differences were seen in the
FBR between the hardest (Pt, Youngs modulus 168 GPa) and
the softest (Naﬁon, Youngs modulus 600 MPa) materials
tested.
Acute inﬂammation begins immediately following
implantation and can last up to 5 days.107 The extent of the
acute inﬂammatory response is related to initial trauma
caused by the insertion device, whereas biosensor size has a
greater effect on chronic inﬂammation and the ﬁbrous
encapsulation.108 Polymorphonuclear leukocytes are the pre-
dominant inﬂammatory cell typically present immediately
following and up to 2 days post-implantation.11 This acute
inﬂammatory reaction was assessed through neutrophil
numbers using an antibody targeting the Ly6G protein. Ly6G
is a glycosylphosphatidylinositol-anchored protein, also
known as the myeloid differentiation antigen Gr1. The anti-
gen is transiently expressed on monocytes in the bone mar-
row and on eosinophils109; however, it is predominantly
expressed on neutrophils and is a commonly used marker
for murine neutrophils.110 In this study, as the percentage of
cells that stained positive for Ly6G/-6C was considerably
lower than the percentage obtained for the F4/80 antibody
(macrophage marker), it is unlikely that any cross reactivity
occurred. Minimal numbers of neutrophils were identiﬁed in
both the untreated xenografts at day 0 and in all tumors at
day 7 post-implantation. These results suggest that the acute
inﬂammatory response resolved normally in the presence of
the biomaterials.
Chronic inﬂammation develops when the inﬂammatory
stimulus (biomaterial) remains at the implantation site and
can last up to 3 weeks following the resolution of acute
inﬂammation; it is marked by the presence of monocytes,
macrophages, and ﬁbroblasts, with the development of neo-
vascularization and the production of granulation and
ﬁbrous tissue.11 Macrophages are the predominant cell type
present that drive the continuing immune response.11,111
Macrophages can phagocytose particles up to 5 μm in size,
however, larger particles (as in the case of biomaterials) will
cause macrophages to coalesce forming foreign body giant
cells (FBGCs).112 Alternatively activated macrophages can
produce proﬁbrogenic factors leading to enhanced ﬁbrogen-
esis by ﬁbroblasts.113 Biomaterial adherent macrophages can
therefore secrete proteins that modulate ﬁbrosis, causing the
deposition of a collagenous, and vascular ﬁbrous capsule
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around the biosensor. This ﬁbrous capsule is the end stage
of the FBR56 and can be 50–200 μm thick.9 In conjunction
with FBGC on the implant surface, the ﬁbrous capsule cre-
ates a barrier conﬁning the implant, preventing it from inter-
acting with the surrounding tissue; this can contribute to a
loss of device function. The potential for this was investi-
gated through macrophage and ﬁbroblast staining, while also
assessing Masson’s trichrome for collagen deposition.
Although it is possible to differentiate between tissue-
resident macrophages and tumor-associated macrophages
(TAMs) in human and mouse tumors, it is challenging to do
so.114 TAMs have been shown to promote tumor cell migra-
tion, invasion, metastasis and the induction of angiogenesis,
all of which are important processes associated with malig-
nant progression.114 Macrophage identiﬁcation was per-
formed using an antibody reactive to murine F4/80, a protein
that has been widely used as a pan-macrophage
marker115,116; as such, we did not distinguish between the dif-
ferent macrophage phenotypes. The observation of a similar
total number of macrophages in both the control and
implanted tumors indicates that the materials did not lead to
the recruitment of additional macrophages. Ongoing tumor
growth may have led to the statistically signiﬁcant increase in
ﬁbroblast number and collagen percentage identiﬁed between
day 0 untreated and day 7 untreated/NT injury tumors.
Since the initial observation by Rygaard and Povlsen117
that human tumors could be successfully grown in athymic
nude mice, various mouse models (including NOD SCID and
CD-1 nude mice) have been extensively used to study the
growth characteristics, metastatic potential, morphology, and
function of numerous xenograft human neoplasms.118,119
CD-1 nude mice were used in this study due to the relative
ease, reproducibility, and speed of producing human xeno-
graft tumors for implantation within this model. Although
athymic nude mice are deﬁcient in thymus derived T lym-
phocytes, they are not fully immunodeﬁcient. Nude mice can
still produce diminished numbers of T lymphocytes via
thymus-independent pathways and can therefore mediate
some degree of T cell dependent immunity.120 They also
show a near-normal response to T-cell-independent antigens
and have high titres of natural antibodies that can react with
tumor cells.121 Tumoricidal macrophages can also be iso-
lated from nude mice, and their activity can be enhanced
after in vivo stimulation with bacterial adjuvants.122 Studies
have also shown that nude mice consistently exhibit a high
level of natural killer (NK) cell activity.123 These studies pro-
vide evidence of the ability of these mice to mount both an
adapted and innate immune response.
The use of T cell deﬁcient mice for investigation of the
FBR to implanted materials has previously been investi-
gated124; this is an important consideration as T cells are
present brieﬂy in the chronic phase of inﬂammation, and
in vivo lymphocyte/macrophage co-cultures demonstrate
that lymphocytes can increase macrophage adhesion to
biomaterial surfaces and enhance the formation of FBGC;
furthermore, the presence of macrophages can stimulate
lymphocytes to proliferate.125 However, the speciﬁc role
for macrophage/lymphocyte interactions has yet to be
identiﬁed, and previous studies have shown that an appro-
priate FBR can occur in the absence of T cells.124 This study
used BALB/c nude mice, which are T-cell deﬁcient through
the lack of a thymus. Although these T-cell-deﬁcient mice
had lower total leukocyte concentrations at the biomaterial
implant site, FBGC morphology, and number were compara-
ble to the BALB/c mice, suggesting that pathways indepen-
dent of thymus-matured T lymphocytes can still lead to a
normal FBR following biomaterial implantation. Using non-
immunosuppressed models, such as carcinogen-induced
tumors, would create tumors in the presence of an intact
immune system; however, the model would not then have
the beneﬁt of using xenografted human tumor cells and
therefore would not assess the effects of the implanted bio-
materials on a human cancer.
The pathological equivalence of nude mice xeno-
transplanted human tumors and naturally occurring tumors
in humans needs to be considered, as there is evidence that
changes in tumor characteristics (histological classiﬁcation
and proliferation rates) can occur after transplanta-
tion.118,119 The murine host response to the presence of
human cancer cells/tissue is another factor that needs to be
considered when using CD-1 nude mice. In human cancers
macrophages are uniformly distributed throughout tumor
tissue.126 While this distribution was seen in some of the
tumors analyzed in this study, a number of tumors had mac-
rophages predominately localized toward the outside of the
cancer tissue (Figure 7). This type of macrophage positioning
has been documented in previous studies and may be
explained by the macrophages associating with the forma-
tion of a ﬁbrous capsule surrounding the tumor itself.126
Whether or not the localization of immune cells within/
around a human xenograft tumor would affect the FBR to an
implanted material is unknown; however, as we saw an
equal mixture of macrophage distributions in control and
implanted tumors, the effect is likely to be minimal.
FIGURE 7. Macrophage (F4/80) distribution types within untreated xeno-
graft tumors. (A) Macrophages are identiﬁed both at the periphery of
the tumor and within the tumor tissue. (B) Macrophages are uniformly
distributed within the tumor tissue.
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Differences in the structure and function of mice and
human immune systems also need to be considered when
evaluating data from mice studies and extrapolating it to
humans. A comprehensive comparative study/review inves-
tigated differences in the immune system in a range of spe-
cies, including CD-1 mice and humans.127 One potentially
relevant ﬁnding to our study was that circulating leukocyte
populations have marked species differences. They stated
that the circulating leukocyte proﬁle in whole blood for
humans is considered to be neutrophilic, having approxi-
mately 50–70% neutrophils (3500–7000 cells/μL) and
20–40% lymphocytes (1400–4000 cells/μL), whereas in CD-
1 mice there is a greater percentage of circulating lympho-
cytes; 15–20% neutrophils (300–2000 cells/μL) and
50–70% lymphocytes (1000–7000 cells/μL). In addition to
differences in the absolute numbers of circulating leuko-
cytes, there are also variations in neutrophil function and
activity between the species. Factors involved in leukocyte
recruitment, such as chemoattractive signals and rolling
adhesion, are known to act though different mechanisms in
both humans and mice.128 Composition of neutrophil gran-
ules also vary between mouse and human neutrophils; for
example, mice lack defensins, which can determine their
antimicrobial mode of action.128 These differences in circu-
lating leukocyte number and function could potentially
result in an alteration in the initiation and progression of a
FBR between the two species, as neutrophils are required in
the initial acute inﬂammatory phase11 and lymphocytes are
transiently present in the chronic phase of the FBR.125
Nitric oxide (NO) is known to have a role in the immune
system, inﬂuencing the activity of many different immune cell
types.129 NO has also been shown to have an effect on the
FBR, with increased NO levels leading to a reduced FBR.130
While studies have shown that mouse macrophages have the
ability to produce NO, there are differing reports on the ability
of human macrophages to generate NO128; variations in NO
production may therefore lead to a difference in the FBR
between the two species. Divergences in the immune systems
of mice and humans, highlighted here using neutrophils, lym-
phocytes, and macrophages as examples, emphasize the need
for caution when attempting to directly translate data from
murine disease models to human pathologies.
Endotoxin testing was not carried out on the materials
used in this study. This may have been a confounding factor
if any of the materials had produced a signiﬁcant inﬂamma-
tory response in implanted tumors compared with the con-
trols. The percutaneous method employed, either to implant
the materials within the tumors or cause a NT injury in con-
trol tumors, also had the potential to introduce endogenous
cutaneous bacterial or endotoxins inside the tumor. However,
protocols to minimize these issues were used, such as aseptic
skin preparation, wire sterilization, along with minimal anes-
thesia and surgery time.131 No visible signs of inﬂammation
occurred at the implant site, all mice remained healthy for
the duration of the experiment, and the control and
implanted tumors did not differ in terms of inﬂammation;
these results suggest that the potential confounding factors
noted above were not an issue. A previous study used a
similar percutaneous method to evaluate the FBR in mice.
Nylon mesh was loaded into a 16-gauge needle, which was
inserted subcutaneously, and a sterile syringe plunger was
used to push the implant into the subcutaneous tissue.116
Sham mice also underwent a NT injury similar to our proce-
dure. The advantages of our model over this study is that a
much smaller gauge of material or needle (for NT injury)
was used; this is an important consideration in any FBR
model, as the extent of the acute inﬂammatory response is
related to the initial trauma caused by the insertion
device.108
Biomaterial effects were assessed for 7 days post-
implantation; this time period includes the acute inﬂamma-
tory response and the beginnings of the chronic inﬂamma-
tory response. For full evaluation of the chronic inﬂammatory
response, materials would need to be implanted for up to
3 weeks, a time frame which would be difﬁcult to achieve
using a murine model. However, Parylene-C implantation was
conducted up to 14 days post-implantation (data not shown),
which produced results similar to those described here.
CONCLUSION
This is the ﬁrst, crucial step in determining if SiO2, Si3N4,
Parylene-C, Naﬁon, OG116-31 resin, and Pt are suitable
materials for implantable medical devices placed within a
solid tumor. Our results suggest that the materials caused no
deleterious effects on the tumor and do not trigger a signiﬁ-
cant FBR. However, it should be noted that additional bio-
compatibility testing is required to fully investigate the FBR.
Experiments using functional biosensors, implanted into a
tumor in immunocompetent large animal models for longer
periods, would provide further conﬁdence in the biocompati-
bility of materials included in the sensors produced by the
IMPACT project.
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